Literature DB >> 15227626

Highly active antiretroviral therapy and viral response in HIV type 2 infection.

Christopher Mullins1, Geoffrey Eisen, Stephen Popper, Abdoulaye Dieng Sarr, Jean-Louis Sankale, Judith J Berger, Sharon B Wright, Hernan R Chang, Gerard Coste, Timothy P Cooley, Peter Rice, Paul R Skolnik, Margaret Sullivan, Phyllis J Kanki.   

Abstract

Human immunodeficiency virus type 2 (HIV-2), the second human retrovirus known to cause AIDS, is endemic to West Africa but is infrequently found outside this region. We present a case series of 10 HIV-2--infected individuals treated in the United States. Physicians applied the principles of highly active antiretroviral therapy (HAART), normally used in treating HIV type 1, with modifications considered appropriate for treating HIV-2. CD4+ cell count, HIV-2 virus load, and clinical status were found to correlate well, providing evidence that HIV-2 virus load is useful in managing treatment of patients with HIV-2 who are receiving therapy. However, HAART regimens with predicted efficacy for treatment of HIV type 1 infection are not as efficacious for treatment of HIV-2. Controlled clinical trials of HIV-2-infected patients receiving various HAART regimens are needed to provide therapeutic guidance to the medical community.

Entities:  

Mesh:

Year:  2004        PMID: 15227626     DOI: 10.1086/421390

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients.

Authors:  Rui S Soares; Rita Tendeiro; Russell B Foxall; António P Baptista; Rita Cavaleiro; Perpétua Gomes; Ricardo Camacho; Emília Valadas; Manuela Doroana; Margarida Lucas; Francisco Antunes; Rui M M Victorino; Ana E Sousa
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

2.  Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1).

Authors:  Berta Rodés; Julie Sheldon; Carlos Toro; Laureano Cuevas; Esperanza Pérez-Pastrana; Inmaculada Herrera; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

3.  In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Authors:  Sherie Masse; Xiaozhi Lu; Tatyana Dekhtyar; Liangjun Lu; Gennadiy Koev; Feng Gao; Hongmei Mo; Dale Kempf; Barry Bernstein; George J Hanna; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

4.  Diagnoses of HIV-1 and HIV-2 in England, Wales, and Northern Ireland associated with west Africa.

Authors:  S Dougan; B Patel; J H Tosswill; K Sinka
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

5.  Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.

Authors:  Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

6.  Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Authors:  Sabelle Jallow; Abraham Alabi; Ramu Sarge-Njie; Kevin Peterson; Hilton Whittle; Tumani Corrah; Assan Jaye; Matthew Cotten; Guido Vanham; Samuel J McConkey; Sarah Rowland-Jones; Wouter Janssens
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

7.  Performance characteristics of a new rapid immunochromatographic test for the detection of antibodies to human immunodeficiency virus (HIV) types 1 and 2.

Authors:  H Syed Iqbal; P Balakrishnan; K G Murugavel; Solomon Suniti
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

8.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Authors:  Julia Drylewicz; Sophie Matheron; Estibaliz Lazaro; Florence Damond; Fabrice Bonnet; François Simon; François Dabis; Françoise Brun-Vezinet; Geneviève Chêne; Rodolphe Thiébaut
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

9.  Human immunodeficiency virus type 2 in two Saudi families.

Authors:  Reem S Almaghrabi; Batool Ali; Sahar Al-Thawadi; Magid Abdel Halim; Abdulrahman A Alrajhi
Journal:  Ann Saudi Med       Date:  2011 Jul-Aug       Impact factor: 1.526

10.  A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.

Authors:  Geoffrey S Gottlieb; Serge-Paul Eholié; John N Nkengasong; Sabelle Jallow; Sarah Rowland-Jones; Hilton C Whittle; Papa Salif Sow
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.